HGF/MET signaling pathway activation can occur via MET gene amplification [24], overexpression [25], mutations [26–28] or paracrine and autocrine activation of MET by HGF [29], all of which have been observed in multiple human tumor types [22, 23]. This evidence concerns the gene MET and neoplasm.